loviride has been researched along with HIV Coinfection in 13 studies
loviride: structure given in first source; inhibits virion and recombinant HIV-1 reverse transcriptase
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2x/day) or lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day) to zidovudine-containing background antiretroviral treatment." | 9.09 | Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. ( Atkins, M; Barrett, C; Cooper, DA; Dore, GJ; Goh, LE; Thakrar, B, 1999) |
| "The efficacy and safety of lamivudine in persons coinfected with human immunodeficiency virus (HIV) type 1 and hepatitis B virus (HBV) were examined in the CAESAR study, a randomized placebo-controlled trial assessing the addition of lamivudine (150 mg 2x/day) or lamivudine (150 mg 2x/day) plus loviride (100 mg 3x/day) to zidovudine-containing background antiretroviral treatment." | 5.09 | Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. ( Atkins, M; Barrett, C; Cooper, DA; Dore, GJ; Goh, LE; Thakrar, B, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (84.62) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 1 (7.69) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, SX | 1 |
| Lu, HH | 1 |
| Liu, GY | 1 |
| Ju, XL | 1 |
| Zhu, YY | 1 |
| Staszewski, S | 3 |
| Miller, V | 3 |
| Rehmet, S | 1 |
| Stark, T | 1 |
| De Crée, J | 2 |
| De Brabander, M | 2 |
| Peeters, M | 1 |
| Andries, K | 2 |
| Moeremans, M | 2 |
| De Raeymaeker, M | 1 |
| Pearce, G | 1 |
| Van den Broeck, R | 1 |
| Verbiest, W | 1 |
| Stoffels, P | 2 |
| Carr, A | 1 |
| Emery, S | 1 |
| Kelleher, A | 1 |
| Law, M | 1 |
| Cooper, DA | 2 |
| Boucher, CA | 1 |
| Phair, JP | 1 |
| Montaner, JS | 1 |
| DeMasi, R | 1 |
| Hill, AM | 1 |
| Dore, GJ | 1 |
| Barrett, C | 1 |
| Goh, LE | 1 |
| Thakrar, B | 1 |
| Atkins, M | 1 |
| Chatterton, ML | 1 |
| Scott-Lennox, J | 1 |
| Wu, AW | 1 |
| Scott, J | 1 |
| Gatell, J | 1 |
| Lange, J | 1 |
| Gartland, M | 1 |
| Clarke, JR | 1 |
| Kaye, S | 1 |
| Babiker, AG | 1 |
| Hooker, MH | 1 |
| Tedder, R | 1 |
| Weber, JN | 1 |
| Kober, A | 1 |
| Colebunders, R | 1 |
| Vandercam, B | 1 |
| Delescluse, J | 1 |
| Clumeck, N | 1 |
| Van Wanzeele, F | 1 |
| Boucher, C | 1 |
| Janssen, PA | 1 |
| Bowers, M | 1 |
| Coppedge, B | 1 |
2 reviews available for loviride and HIV Coinfection
| Article | Year |
|---|---|
Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulat | 2018 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N | 1997 |
9 trials available for loviride and HIV Coinfection
| Article | Year |
|---|---|
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
Topics: Acetamides; Acetophenones; Adult; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cros | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug | 1996 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lym | 1998 |
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
Topics: Acetamides; Acetophenones; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Disease Progression; Dise | 1999 |
Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
Topics: Acetamides; Acetophenones; Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; F | 1999 |
AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
Topics: Acetamides; Acetophenones; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug T | 1999 |
Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Codon; DNA; DNA Mutational Analysis; Drug Resistance, Mi | 2000 |
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Biomarkers; CD4 Lymphocyte Count; Double-Blind Method; F | 1996 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clini | 1997 |
2 other studies available for loviride and HIV Coinfection
| Article | Year |
|---|---|
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; | 1996 |
ICAAC update.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Top | 1996 |